Skip to Content

Mozobil (plerixafor) Disease Interactions

There are 3 disease interactions with Mozobil (plerixafor):

Moderate

Plerixafor (applies to Mozobil) leukocytosis

Moderate Potential Hazard, Moderate plausibility.

The use of plerixafor in combination with granulocyte-colony stimulating factor increases leukocytes as well as hematopoietic stem cells populations. Caution should be exercised when administering this agent to patients with peripheral blood neutrophil counts above 50,000/mcL. It is recommended to monitor white blood cell counts during therapy.

Moderate

Plerixafor (applies to Mozobil) renal impairment

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

It is recommended to reduce the dose of plerixafor by one-third to 0.16 mg/kg in patients with moderate to severe renal impairment.

Moderate

Plerixafor (applies to Mozobil) thrombocytopenia

Moderate Potential Hazard, Moderate plausibility.

The use of plerixafor may cause thrombocytopenia. Care and close monitoring are recommended when using plerixafor in patients with thrombocytopenia. Monitor counts in all patients and then undergo apheresis.

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.